A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium
Nivo + Cabo and Pem + Len demonstrated similar oncologic efficacy as first-line treatments for mRCC. However, Pem + Len was associated with more severe TrAEs. Careful toxicity management and shared decision-making are essential when selecting ICI-based combinations.
Authors
- Hirofumi Morinaka
- TERUO INAMOTO
- Tatsushi Kawada (ORCID: https://orcid.org/0000-0002-8369-9712)
- Wataru Fukuokaya (ORCID: https://orcid.org/0000-0003-1044-912X)
- Satoshi Katayama (ORCID: https://orcid.org/0000-0002-8377-2457)
- Masaya Murakami (ORCID: https://orcid.org/0000-0002-1268-6615)
- Takuhisa Nukaya (ORCID: https://orcid.org/0009-0007-9902-1694)
- TAKUYA TSUJINO
- Motoo Araki
- Shingo Toyoda
- JK-FOOT study group
- Ryoichi Maenosono
- Haruhito Azuma
- Keiichiro Mori
- Takahiro Kimura
- Takafumi Yanagisawa
- Kazumasa Komura
- Kiyoshi Takahara
- Kazutoshi Fujita
- Kensuke Bekku
- Keita Tamura
Institutions
- Jikei University School of Medicine (JP)
- Fujita Health University (JP)
- Okayama University (JP)
- Kawasaki Medical School (JP)
- Comprehensive Cancer Center Vienna (AT)
- Hamamatsu Medical Center (JP)
- Medical University of Vienna (AT)
- Osaka University of Pharmaceutical Sciences (JP)
- Kindai University (JP)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1007/s00262-025-04288-6
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00